0.05
-0.0292(-37.29%)
Currency In USD
| Previous Close | 0.08 |
| Open | 0.04 |
| Day High | 0.07 |
| Day Low | 0.04 |
| 52-Week High | 0.07 |
| 52-Week Low | 0.04 |
| Volume | 76,931 |
| Average Volume | 35,973.82 |
| Market Cap | 331,599 |
| PE | -0.03 |
| EPS | -1.73 |
| Moving Average 50 Days | 0.07 |
| Moving Average 200 Days | 0.06 |
| Change | -0.03 |
Cingulate Names Industry Veteran Bryan Downey Chief Commercial Officer to Lead Launch Preparation for CTx-1301
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
Appointment builds on recent FDA acceptance of New Drug Application for review and advances Cingulate’s transition toward commercialization pending FDA approval Company also strengthens its cash position by completing a $6 million financing KANSAS CI
Cingulate Presents Positive Phase 3 Results for CTx-1301 Demonstrating Statistically Significant Efficacy and Entire Active-Day Symptom Control
GlobeNewswire Inc.
Oct 28, 2025 12:00 PM GMT
Once-daily formulation of dexmethylphenidate achieved primary endpoint (p < 0.001) with consistent symptom relief up to 12 hours post-doseKANSAS CITY, Kan., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical compan
Cingulate’s Lead ADHD Candidate CTx-1301 Selected for Podium Presentation at AACAP Annual Meeting
GlobeNewswire Inc.
Oct 23, 2025 8:45 PM GMT
Presentation by ADHD expert Dr. Ann Childress to highlight Phase 3 findings supporting the potential for true, entire active-day symptom controlKANSAS CITY, Kan., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical